Our lawyers are not merely legal experts – they also know and comprehend the specific business issues and complex market conditions of the digital world. We provide specialist advice, integrated across a range of legal disciplines, and a global full-service offering.

Key contacts

Georgina Kon
Partner,
Technology, Data and Commercial
Tel: +44 20 7456 5532
georgina.kon@linklaters.com

Marly Didizian
Global co-head of Healthcare sector,
Technology, Data and Commercial
Tel: +44 20 7456 3258
marly.didizian@linklaters.com

Jana Hager
Counsel,
Corporate/M&A
Tel: +49 30 214 96 318
jana.hager@linklaters.com

Ingemar Kartheuser
Counsel,
TMT
Tel: +49 69 710 03 542
ingemar.kartheuser@linklaters.com

Johanna Pflug
Managing Associate,
Corporate/M&A
Tel: +49 69 710 03 260
johanna.pflug@linklaters.com

Jens Hollinderbäumer
Managing Associate,
Corporate/M&A
Tel: +49 30 214 96 337
jens.hollinderbaeumer@linklaters.com

Georgina Kon
Partner,
Technology, Data and Commercial
Tel: +44 20 7456 5532
georgina.kon@linklaters.com

This publication is intended merely to highlight issues and not to be comprehensive, nor to provide legal advice. Should you have any questions on issues reported here or on other areas of law, please contact one of your regular contacts, or contact the editors.

© Linklaters LLP. All Rights reserved 2018

Linklaters LLP is a limited liability partnership registered in England and Wales with registered number OC326345. It is a law firm authorised and regulated by the Solicitors Regulation Authority. The term partner in relation to Linklaters LLP is used to refer to a member of Linklaters LLP or an employee or consultant of Linklaters LLP or any of its affiliated firms or entities with equivalent standing and qualifications. A list of the names of the members of Linklaters LLP together with a list of those non-members who are designated as partners and their professional qualifications is open to inspection at its registered office, One Silk Street, London EC2Y 8HQ or on www.linklaters.com and such persons are either solicitors, registered foreign lawyers or European lawyers.

Please refer to www.linklaters.com/regulation for important information on our regulatory position.
Digital Health and Linklaters: A holistic approach

**Highlights of our digital health experience includes advising:**

- **a leading healthcare provider** on a virtual consultation app designed to be made available in a number of jurisdictions in Europe, Asia and the Middle East, including on the privacy, IT, commercial and medical device issues arising.
- **a healthcare insurer** on the use of data analytics generally and on the commercial terms, medical device, privacy and product liability issues relating to its rollout of a vDNA service in the context of its accelerator programme. The service combined data obtained from wearables and human samples to provide health and wellbeing recommendations to individuals.
- **the Royal Free** on use of an App developed by DeepMind (part of the Google group of companies). We conducted an audit, which included a detailed review of the technology underpinning the App and data protection and confidentiality laws.
- **a global healthcare manufacturer** on the commercialisation of a tele-monitoring and patient management application designed to monitor and optimise the treatment of patients who suffer from sleeping disorders.
- **a healthcare device start-up** on cooperation agreement with a pharmaceutical company in the context of clinical trials.
- **one of the leading repositories of genomic data** in the world on a range of commercial, technology, public law, competition/state aid, privacy and corporate governance issues relating to its achievement of its public interest and commercial objectives, including in relation to potential partnerships and arrangements with health services.
- **Johnson & Johnson** on the competition law issues relating to its joint venture with Google for the creation of a comprehensive surgical solutions platform that will incorporate leading-edge robotic capabilities and best-in-class medical device technology.
- **a pharmaceutical company** on all aspects of its contract for cloud-based clinical trial services.
- **a number of NGOs** on the regulatory issues affecting the collection and centralised electronic storage of medical information obtained by doctors from their work in emerging markets, and in relation to the data centre solution for the same.
- **Wyeth (now Pfizer)** on a joint venture with Mobistar (Orange Group) for the commercialisation of an app for haemophiliac patients.
- **a biotech company** on its market entry in several jurisdictions, including on the EU tissue directives and supply and cooperation agreements.
- **Elsevier Limited** on its acquisition of 100% of InferMed Limited, a clinical decision support technology company.
- **Neuravi**, an innovative medical devices creator for neurointerventional therapy, on its sale to Johnson & Johnson.
- **Vivaneo** on its acquisition of MIM Medizinische Instrumente & Monitoring GmbH, Advanced Respiratory Care AG and Acutronic Medical Systems AG, including advice on medical device regulation in several countries, including Japan, China, Thailand and Europe.

**What our clients say about us:**

“Linklaters LLP has ‘extensive experience and knowledge in the healthcare sector’. The team amply draws on its expertise in all areas of corporate finance, M&A, banking, IP, data protection and outsourcing, product liability, regulatory and antitrust projects; according to one client, it demonstrates ‘extraordinary commitment to and responsiveness to overcome challenges that clients’ businesses face within the industry’.”

Legal 500 EMEA 2018, TMT (Pharmaceuticals and biotechnology): UK

“They have great responsiveness and quality, and they know what is going on in different sectors.”

Chambers UK 2019, Data protection

“Their ability to deploy knowledge and capable people is strong, there is depth to the team. The environment is truly international and cross-border.”

Chambers Global 2018, TMT

“Highly expert but also able to deliver that expertise in a meaningful way that adds to the value of the deal.”

Chambers UK 2018, Information technology: London